Advanced glycation end-product formation pathways (AGE formation pathways)

Advanced glycation end-products (AGEs) are a heterogeneous group of compounds formed through the non-enzymatic reaction between reducing sugars and the amino groups of proteins, lipids, or nucleic acids, a process known as the Maillard reaction (Singh et al., 2014). This pathway begins with the formation of unstable Schiff bases and Amadori products, which eventually undergo complex rearrangements, dehydration, and cross-linking to form irreversible AGEs that accumulate in tissues over time (StatPearls, 2023). In pathological states such as chronic hyperglycemia in diabetes or increased oxidative stress, the accumulation of AGEs leads to structural damage of long-lived proteins like collagen and activates the Receptor for Advanced Glycation End-products (RAGE), triggering pro-inflammatory and pro-oxidative signaling (Bierhaus et al., 2005). Therapeutic strategies targeting these pathways include the use of carbonyl scavengers to neutralize reactive intermediates, inhibitors of Amadori-to-AGE conversion, and AGE-breakers designed to cleave existing cross-links (Vistoli et al., 2013). While several candidates like aminoguanidine and pyridoxamine have shown promise in preclinical models for treating diabetic complications and neurodegenerative diseases, clinical translation has been challenging due to safety concerns and variable efficacy (Ahmed, 2005).

Other names

Maillard reactionProtein glycationNon-enzymatic glycosylationAGE-RAGE axisCarbonyl stress pathways

Therapeutic intervention involves the scavenging of reactive carbonyl species (RCS) such as methylglyoxal and glyoxal, inhibition of the conversion of Amadori products into stable AGEs, and the chemical cleavage of established alpha-diketone-derived protein cross-links (Vistoli et al., 2013; Ahmed, 2005).